Complete eradication of xenograft hepatoma by oncolytic adenovirus ZD55 harboring TRAIL-IETD-smac gene with broad antitumor effect

Human Gene Therapy

Volumn 23, Issue 9, 2012, Pages 992-1002

  Wang, Shi Bing ^a,b   Tan, Yuan ^a   Lei, Wen ^a   Wang, Yi Gang ^a   Zhou, Xiu Mei ^a   Jia, Xiao Yuan ^a   Zhang, Kang Jian ^a   Chu, Liang ^a   Liu, Xin Yuan ^a,c   Qian, Wen Bin ^a,b  

^a ZHEJIANG SCI TECH UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 8; HYBRID PROTEIN; ONCOLYTIC ADENOVIRUS; ONCOLYTIC ADENOVIRUS ZD55; TRAIL IETD SMAC PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; FUSION GENE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN PURIFICATION; TUMOR XENOGRAFT;

ADENOVIRIDAE; ANIMALS; CARCINOMA, HEPATOCELLULAR; CASPASE 8; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; HELA CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOCHONDRIAL PROTEINS; NEOPLASM TRANSPLANTATION; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; RECOMBINANT FUSION PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

ADENOVIRIDAE;

EID: 84866341879     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2011.159     Document Type: Article

References (34)

1. Ashkenazi, A. (2002). Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat. Rev. Cancer 2, 420-430. (Pubitemid 37328939)
2. Bischoff, J.R., Kirn, D.H., Williams, A., et al. (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373-376. (Pubitemid 26353341)
3. Breitbach, C.J., Burke, J., Jonker, D., et al. (2011). Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477, 99-102.
4. Carrillo, C., Tulman, E.R., Delhon, G., et al. (2005). Comparative genomics of foot-and-mouth disease virus. J. Virol. 79, 6487-6504. (Pubitemid 40617252)
5. Chai, J., Du, C., Wu, J.W., et al. (2000). Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature 406, 855-862. (Pubitemid 30664254)
6. Chappell, S.A., Edelman, G.M., and Mauro, V.P. (2000). A 9-nt segment of a cellular mRNA can function as an internal ribosome entry site (IRES) and when present in linked multiple copies greatly enhances IRES activity. Proc. Natl. Acad. Sci. U.S.A. 97, 1536-1541. (Pubitemid 30118477)
7. Chu, L., Gu, J., He, Z., et al. (2006). Adenoviral vector expressing CYLD augments antitumor activity of TRAIL by suppression of NF-jB survival signaling in hepatocellular carcinoma. Cancer Biol. Ther. 5, 615-622. (Pubitemid 44024715)
8. Deng, Y., Lin, Y., and Wu, X. (2002). TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev. 16, 33-45. (Pubitemid 34049636)
9. Dix, B.R., Edwards, S.J., and Braithwaite, A.W. (2001). Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway? J. Virol. 75, 5443-5447. (Pubitemid 32488136)
10. Du, C., Fang, M., Li, Y., et al. (2000). Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102, 33-42.
11. Ehrhardt, H., Hacker, S., Wittmann, S., et al. (2008). Cytotoxic drug-induced, p53-mediated upregulation of caspase-8 in tumor cells. Oncogene 27, 783-793. (Pubitemid 351186307)
12. Evans, J. (2011). Recent deal highlights hopes for cancer-killing viruses. Nat. Med. 17, 268-269.
13. Fang, J., Qian, J.J., Yi, S., et al. (2005). Stable antibody expression at therapeutic levels using the 2A peptide. Nat. Biotechnol. 23, 584-590. (Pubitemid 41724897)
14. Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell 100, 57-70. (Pubitemid 30046295)
15. Hudder, A., and Werner, R. (2000). Analysis of a Charcot-Marie-Tooth disease mutation reveals an essential internal ribosome entry site element in the connexin-32 gene. J. Biol. Chem. 275, 34586-34591.
16. Kroemer, G., Galluzzi, L., and Brenner, C. (2007). Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 87, 99-163. (Pubitemid 46209992)
17. Levinson, A.D. (2010). Cancer therapy reform. Science 328, 137.
18. Lin, T., Gu, J., Zhang, L., et al. (2002). Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes. Cancer Res. 62, 3620-3625. (Pubitemid 34728835)
19. Liu, X.Y., Qiu, S.B., Zou, W.G., et al. (2005). Effective genevirotherapy for complete eradication of tumor mediated by the combination of hTRAIL (TNFSF10) and plasminogen k5. Mol. Ther. 11, 531-541.
20. Marshall, E. (2011). Cancer research and the $90 billion metaphor. Science 331, 1540-1541.
21. Mattion, N.M., Harnish, E.C., Crowley, J.C., and Reilly, P.A. (1996). Foot-and-mouth disease virus 2A protease mediates cleavage in attenuated Sabin 3 poliovirus vectors engineered for delivery of foreign antigens. J. Virol. 70, 8124-8127. (Pubitemid 26339123)
22. Mizuguchi, H., Xu, Z., Ishii-Watabe, A., et al. (2000). IRESdependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol. Ther. 1, 376-382.
23. Ngoi, S.M., Chien, A.C., and Lee, C.G. (2004). Exploiting internal ribosome entry sites in gene therapy vector design. Curr. Gene Ther. 4, 15-31. (Pubitemid 38854943)
24. Pan, G., O'Rourke, K., Chinnaiyan, A.M., et al. (1997). The receptor for the cytotoxic ligand TRAIL. Science 276, 111-113. (Pubitemid 27161256)
25. Pei, Z., Chu, L., Zou, W., et al. (2004). An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology 39, 1371-1381. (Pubitemid 38569059)
26. Saelens, X., Festjens, N., Vande Walle, L., et al. (2004). Toxic proteins released from mitochondria in cell death. Oncogene 23, 2861-2874. (Pubitemid 38638848)
27. Schneider, P., Bodmer, J.L., Thome, M., et al. (1997). Characterization of two receptors for TRAIL. FEBS Lett. 416, 329-334. (Pubitemid 27475391)
28. Sheridan, J.P., Marsters, S.A., Pitti, R.M., et al. (1997). Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277, 818-821. (Pubitemid 27366733)
29. Shi, Y. (2002). Mechanisms of caspase activation and inhibition during apoptosis. Mol. Cell 9, 459-470. (Pubitemid 34273778)
30. Srinivasula, S.M., Datta, P., Fan, X.J., et al. (2000). Molecular determinants of the caspase-promoting activity of Smac/DIABLO and its role in the death receptor pathway. J. Biol. Chem. 275, 36152-36157.
31. Zhang, Y., Gu, J., Zhao, L., et al. (2006). Complete elimination of colorectal tumor xenograft by combined manganese superoxide dismutase with tumor necrosis factor-related apoptosisinducing ligand gene virotherapy. Cancer Res. 66, 4291-4298.
32. Zhang, Z., Huang, Y., Newman, K., et al. (2009). Reexpression of human somatostatin receptor gene 2 gene mediated by oncolytic adenovirus increases antitumor activity of tumor necrosis factor-related apoptosis-inducing ligand against pancreatic cancer. Clin. Cancer Res. 15, 5154-5160.
33. Zhang, Z.L., Zou, W.G., Luo, C.X., et al. (2003). An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Res. 13, 481-489. (Pubitemid 43231842)
34. Zhao, L., Dong, A., Gu, J., et al. (2006). The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer. Cancer Gene Ther. 13, 1011-1022. (Pubitemid 44564737)